CTA
ACAD icon

Carillon Tower Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Carillon Tower Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-715,382
Closed -$28.1M – 462
2020
Q1 		$28.1M Hold
715,382
– – 0.28% 128
2019
Q4 		$30.6M Hold
715,382
– – 0.2% 176
2019
Q3 		$25.7M Hold
715,382
– – 0.18% 204
2019
Q2 		$19.1M Buy
+715,382
New +$18.3M 0.13% 258

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Carillon Tower Advisers's ACAD Position: Q2 2020 in Review

Carillon Tower Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 715,382 shares — an estimated $28.1M sold.

Carillon Tower Advisers first reported a position in ACAD in Q2 2019 and held it in 4 quarters. The position peaked at $30.6M in Q4 2019. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • Carillon Tower Advisers reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Carillon Tower Advisers sold 715,382 Acadia Pharmaceuticals shares in Q2 2020, an estimated $28.1M.
  • Carillon Tower Advisers first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Carillon Tower Advisers's Acadia Pharmaceuticals position peaked at $30.6M in Q4 2019.
  • 298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on Carillon Tower Advisers's 13F filing for Q2 2020, filed 12 Aug 2020.